

Apitegromab: From ONYX to Commercial Product

Avoid interruptions in care

As of September 11, 2026, ISEMBYLD™ (apitegromab-mstn) has become commercially available. Scholar Rock is committed to ensuring seamless continuity of treatment with apitegromab for children and adults in the ONYX clinical trial, and we understand that patients will require insurance approval before starting on commercial product. Follow this step-by-step process to help transition appropriate patients to ISEMBYLD.

Get the Scholar Rock Supports™ enrollment form and other support resources at

ScholarRockSupports.com/hcp



Questions? Contact Scholar Rock Supports and your dedicated ROCC:
1-833-777-5444

M–F, 8AM–8PM ET



ISEMBYLD and Scholar Rock Supports are trademarks of Scholar Rock. Scholar Rock © 2026. All rights reserved.
US-APIT-0417 09/26

5 STEPS TO TRANSITION APPROPRIATE PATIENTS TO ISEMBYLD

1 Submit the enrollment form

After you decide that a patient from the ONYX trial will continue treatment with apitegromab, the **Scholar Rock Supports enrollment form** activates support for your patient, including affordability programs and guidance navigating insurance. In addition, you can indicate whether treatment continues at your site, at home, or through another hospital or infusion center. Key details you will need to include:

- Patient's weight-based dose based on FDA-approved Prescribing Information
- Patient's insurance information
- Preferred infusion location
- Prescriber signature and date
- Patient, caregiver, or legal representative signature

Be sure to select "Yes" for Apitegromab Clinical Trial Participant and include the program ID (eg, xxx-xxx).

2 Connect with your ROCC

The Scholar Rock Supports Rx Onboarding and Care Coordinator (ROCC) **will initiate a welcome call with your patient and contact your office** to determine patient support needs.

3 Verify benefits

Scholar Rock Supports can run a benefits investigation to determine coverage for ISEMBYLD and its administration based on the patient's insurance plan benefits and individual needs. In addition to **confirming the in-network specialty pharmacy for patients transitioning to or staying on home infusion**, Scholar Rock Supports can help verify benefits for infusions taking place at a hospital or infusion center.

4 Obtain insurance approval

If a prior authorization (PA) is required, **your ROCC can provide educational resources and support** about the PA and reauthorization process, and help determine documentation needed to submit an accurate and complete PA packet.

5 Schedule commercial dose

Arrange for commercial dose shipment and schedule the administration date. The end-of-treatment/end-of-study (EOT/EOS) visit may then be scheduled. This ensures a seamless transition from the patient's last ONYX dose.

